NKNorman M. Kneteman

Norman M. Kneteman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Norman M. Kneteman has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Type II fibre atrophy and nuclear disruption in decompensated cirrhosis

    by Maryam Motamedrad, Maryam Ebadi, Norberto Sanchez-Fernandez, Alessandro Parente, Abha R. Dunichand-Hoedl, Elora Rider, Norman M. Kneteman, A.M. James Shapiro, David Bigam, Khaled Dajani, et al.


  • Additive effect of sirolimus and anti‐death receptor 5 agonistic antibody against hepatocellular carcinoma

    by Toshiyasu Kawahara, Christian Toso, Keisuke Yamaguchi, Sonia Cader, Donna N. Douglas, Mahra Nourbakhsh, Jamie T. Lewis, Thomas A. Churchill, Hideo Yagita, Norman M. Kneteman

    Background & Aims: Despite careful patient selection, hepatocellular carcinoma (HCC) recurs in 10–20% of cases after liver transplantation, and the use of potent adjuvant anticancer drugs would be welcome. The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti‐death receptor (DR)5 monoclonal antibody (mAb) on HCC.Methods: We first assessed the side effects of anti‐DR5 mAb administration in vivo by giving various doses of anti‐DR5 mAb. Cell proliferation assays were then performed using mouse Hepa1‐6 cells or human Huh7 cells to quantify the relative cell viability under various concentrations of sirolimus, anti‐DR5 mAb or a combination. Next, one million Hepa1‐6 cells were transplanted into C.B17‐SCID‐beige mice subcutaneously, and four groups were created: (1) untreated, (2) anti‐DR5 mAb alone, (3) sirolimus alone and (4) anti‐DR5 mAb + sirolimus.Results: Anti‐DR5 mAb (200 and 300 μg/day) induced liver dysfunction with partial necrosis of the liver, but 100 μg/day was well tolerated with transaminitis, but normal bilirubin and only minor histological liver damage. In vitro, anti‐DR5 mAb lysed Hepa1‐6 and Huh7 cells in a dose‐dependent manner, and combinations of sirolimus and anti‐DR5 mAb demonstrated an additive effect. In vivo studies demonstrated that tumour sizes were significantly smaller in the combined therapy group than in the monotherapy groups.Conclusions: Combining sirolimus and low‐dose anti‐DR5 mAb has a significant effect against HCC. This strategy represents a potential novel approach for the management of HCC.


  • Open Access

    TACROLIMUS (FK506)-ITS EFFECTS ON INTESTINAL GLUCOSE TRANSPORT1

    by Natalie L. Yanchar, Timothy M. Riegel, Gary Martin, Richard N. Fedorak, Norman M. Kneteman, David L. Sigalet

    Tacrolimus (FK506) is at present the mainstay of immunosuppression for small intestinal transplantation. This study investigates the effects of chronic treatment with varying dosages of tacrolimus on animal well-being, weight gain, intestinal permeability, and the active transport of nutrients as measured by in vitro studies quantifying glucose flux. The effect of acute treatment with high-dose tacrolimus on glucose flux was also investigated. In the chronic studies, juvenile male Lewis rats were given tacrolimus in a dosage of 0.1 mg/kg, 0.5 mg/kg, and 2 mg/kg q. second day by subcutaneous injection for five weeks. In the acute studies, animals were treated with 2 mg/kg given q. 24 hr [mult] 48 hr, 24 hr and 12 hr prior to sacrifice. In the acute treatment groups, tacrolimus caused no change in glucose flux. In the chronically treated animals, FK506 levels were within the clinically relevant range. Chronic treatment with 0.5 and 2 mg/kg caused a significant reduction in weight gain. These same groups of animals had a significant increase in intestinal permeability as measured by absorption of 99Te-DTPA. Glucose flux was affected in all chronically treated groups, with net flux increasing in the jejunum and decreasing in the ileum. These findings show that chronic treatment with low-dose tacrolimus is well tolerated, but in higher doses there are significant effects in intestinal permeability and nutrient uptake, and animal weight gain. We suggest that these changes are due to alterations in intestinal permeability that do not appear to be mediated by an acute drug effect and more likely represent chronic changes, possibly from alterations in gene expression. These findings suggest that further studies regarding the effects of tacrolimus on nutrient transport, intestinal permeability, and the known immunologically related functions of tacrolimus should be done.